Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US$1 million
Read More: Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US$1 millionHow Rakovina Therapeutics designed a novel, brain-penetrant ATR inhibitor with Enki™: one design cycle to four IP-clear lead series, five optimization cycles to sub-nanomolar potency, 122 compounds, about two years, US$1M of direct external spend. Full PDF available. Read More about Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US class=”wp-block-post-excerpt__more-link” href=”https://variational.ai/news/use-case/case-study-brain-penetrant-atr-inhibitor-kt-5000/” million
Our Latest News
Featured
Blog & Press
Variational AI Named “Gamechanger – AI” at BC Tech’s 2026 Technology Impact Awards
Variational AI is proud to announce that it has been named the winner of the Gamechanger – AI award at the BC Tech Association’s 2026 Technology Impact Awards (TIAs) Read More about Variational AI Named “Gamechanger – AI” at BC Tech’s 2026 Technology Impact Awards
Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US$1 million
How Rakovina Therapeutics designed a novel, brain-penetrant ATR inhibitor with Enki™: one design cycle to four IP-clear lead series, five optimization cycles to sub-nanomolar potency, 122 compounds, about two years,… Read More about Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US class=”wp-block-post-excerpt__more-link” href=”https://variational.ai/news/use-case/case-study-brain-penetrant-atr-inhibitor-kt-5000/” million
SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
Variational AI has entered a research collaboration with SK Life Science Labs, the U.S. discovery research subsidiary of SK Biopharmaceuticals. Variational AI will use its Enki™ generative AI platform to… Read More about SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Vancouver-based 3C Therapeutics to apply Variational AI’s Enki™ platform to ligand design for proprietary TriCore DAC platform under Innovate BC’s Integrated Marketplace program Read More about 3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel… Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI is pleased to share that Enamine has joined the Agora Open Science Trust collaboration focused on discovering novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), a… Read More about Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Upcoming Events
No events found.
Media & Resources
Variational AI featured in AWS’s “Canada’s AI Innovators” series
Variational AI is one of nine companies featured in AWS’s Canada’s AI Innovators series, recognising how our Enki™ generative AI platform is making small molecule drug discovery 100x more efficient. Read More about Variational AI featured in AWS’s “Canada’s AI Innovators” series
AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
In this conversation, Handol shares how his team is rethinking drug discovery using generative AI, tackling one of the most complex and high-stakes challenges in science. From a 25-year career… Read More about AI, Drug Discovery & Startups: A Candid Talk with Handol Kim, CEO of Variational AI
How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
From Handshake to Breakthrough: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording) In this 60-minute fireside chat, Rakovina Therapeutics and Variational AI share the story behind… Read More about How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
What’s with RWE Podcast: Generative AI for Drug Discovery
Handol Kim, CEO of Variational AI, shares insights on the growing role of generative AI in pharmaceutical research. The discussion highlights how advanced machine learning approaches can help researchers explore… Read More about What’s with RWE Podcast: Generative AI for Drug Discovery